Orally administered peptides to ameliorate atherosclerosis

Details Orally administered peptides to ameliorate atherosclerosis Orally administered peptides to ameliorate atherosclerosis

2006-12-05

2006-12-05

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S326000

Reexamination Certificate

active

07144862

ABSTRACT:
This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. In certain embodiments, the peptide comprises an amino acid sequence that ranges in length from about 10 up to about 30 amino acids, that comprises at least one class A amphipathic helix, that bears at least one protecting group, that protects a phospholipid against oxidation by an oxidizing agent; and that is not the D-18A peptide. The peptides are highly stable and readily administered via an oral route.

REFERENCES:
patent: 3767040 (1973-10-01), Tushaus
patent: 4155913 (1979-05-01), Hellerbach et al.
patent: 4643988 (1987-02-01), Segrest et al.
patent: 4684520 (1987-08-01), Bertelli
patent: 5298490 (1994-03-01), Heavner et al.
patent: 5344822 (1994-09-01), Levine et al.
patent: 5595973 (1997-01-01), Bogden
patent: 5721138 (1998-02-01), Lawn
patent: 5733549 (1998-03-01), Yamada et al.
patent: 5733879 (1998-03-01), Rosseneu et al.
patent: 5814467 (1998-09-01), Curtiss et al.
patent: 5854238 (1998-12-01), Kempen
patent: 6004925 (1999-12-01), Dasseux et al.
patent: 6037323 (2000-03-01), Dasseux et al.
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6046166 (2000-04-01), Dasseux et al.
patent: 6086918 (2000-07-01), Stern et al.
patent: 6265377 (2001-07-01), Dasseux et al.
patent: 6287590 (2001-09-01), Dasseux
patent: 6329341 (2001-12-01), Dasseux et al.
patent: 6376464 (2002-04-01), Dasseux et al.
patent: 6455088 (2002-09-01), Dasseux
patent: 6518412 (2003-02-01), Dasseux et al.
patent: 6573239 (2003-06-01), Dasseux et al.
patent: 6602854 (2003-08-01), Dasseux et al.
patent: 6630450 (2003-10-01), Dasseux et al.
patent: 6664230 (2003-12-01), Fogelman et al.
patent: 6696545 (2004-02-01), Buelow et al.
patent: 6716816 (2004-04-01), Dasseux et al.
patent: 6734169 (2004-05-01), Dasseux et al.
patent: 6753313 (2004-06-01), Dasseux et al.
patent: 2001/0005714 (2001-06-01), Boffelli et al.
patent: 2002/0042441 (2002-04-01), Acton et al.
patent: 2003/0027769 (2003-02-01), Scialdone et al.
patent: 2003/0040505 (2003-02-01), Fogelman et al.
patent: 2003/0045460 (2003-03-01), Fogelman et al.
patent: 2003/0125260 (2003-07-01), Haviv et al.
patent: 185761 (2004-04-01), None
patent: WO 96/41815 (1996-12-01), None
patent: WO 97/36927 (1996-12-01), None
patent: WO 97/36927 (1997-10-01), None
patent: WO 98/09602 (1998-03-01), None
patent: WO 99/16408 (1999-04-01), None
patent: WO 99/47566 (1999-09-01), None
Kuller et al. The Relation between Serum Albumin Levels and Risk of Coronary Heart Disease . . . American Journal of Epidemiology. 1991, vol. 134, No. 11, pp. 1266-1277.
Anantharamaiah (1986) “Synthetic Peptide Analogs of Appolipoproteins.”Methods in Enzymology128:627-647.
Anantharamaiah and Garber (1996) “Chromatographic Methods for Quantitation of Apolipoprotein A-I.”Meth. Enzymol.263:267-282.
Anantharamaiah et al. (1985) “Studies of Synthetic Peptide of the Amphipathic Helix.”The Journal of Biological Chemistry260:10248-10255.
Anantharamaiah et al. (1990) “Use of Synthetic Peptide Analogues to Localize Lecithin: Cholseterol Acyltransferase Activating Domain in Apolipoprotein A-I.”Arteriosclerosis10:95-105.
Anantharamaiah et al. (1993) “An Atlas of the Amphipathic Helical Domains of Human Exchangeable Plasma Apolipoproteins.” Chapter. 6:109-142 In:The Amphipathic Helix(Epand, R.M., ed), CRC Press, Boca Raton, FL.
Armstrong et al. (1993) D amino acid levels in human physiological fluids,Chirality, 5: 375-378.
Badimon et al. (1990) “Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit.”J. Clinical Investigation85:1234-1241.
Bauer et al. (1982) “SMS 201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action”Life Sciences31:1133-1140.
Boffelli et al. (1997) “Reconstitution and Further Characterization of the Cholesterol Transport Activity of the Small-Intestinal Brush Border Membrane”Biochemistry36:10784-10792.
Boffelli et al. (1997) “The uptake of cholesterol at the small-intestinal brush border membrane is inhibited by apolipoproteins.” FEBS Letters, 411:7-11.
Borhani et al. (1999) “Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation.”Proc. Natl. Acad. Sci. USA.94:12291-12296.
Brouillette and Anantharamaiah (1995) “Structural models of human apolipoprotein A-I.”Biochem. Biophys. Acta1256: 103-129.
Brouillette et al. (2001) “Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review”Biochemica et Biophysica Acta55753:1-44.
Canadian Pharmacists Association, Starlix General Monograph, http://cpha.infinetcomm.com/content/hcp/tools/cps13cnp—updates/starlix.cfm (2002).
Chung et al. (1985) “Studies of Synthetic Peptide Analogs of the Amphipathic Helix.”J. Biol. Chem.60(18): 10256-10262.
Datta et al. (2001) Effects of Increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helicat Peptide.J Lipid Research42:1096-1104.
Davison et al. (1994) “The Influence of Apolipoprotein Structure on the Efflux of Celluar Free Cholesterol to High Density Lipoprotein.”J. Biol. Chem.269(37):22975-22982.
Diederich et al. (2001) “Apolipoprotein AI and HDL3Inhibit Spreading of Primary Human Monocytes through a Mechanism that Involves Cholesterol Depletion and Regulation of CD42.”Atherosclerosis159:313-324.
Dooley et al. (1994) “An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library”Science2019-2022.
Dunlop and Neidle (1997) “The Orgion and Tunover of D-Serine in Brain,”Biochemical and Biophysical Research Communication235:26-30.
Ehara et al. (2001) “Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes.”Circulation103:1955-1960.
Epand et al. (1987) “Studies Synthetic Peptide Analog of the Amphipatic Helix”J. Biol. Chem.262(19): 9389-9396.
Field et al. (2001) “Gene expression of sterol regulatory element-binding proteins in hamster small intestine.”Journal of Lipid Research42:1-9.
Fielding and Fielding (1995) “Molescular Physiology of reverse chlesterol transport,”J. Lipid Res.36:211-228
Fielding et al. (1972) “A Protein of Lecithin: Cholester Acyltransferase.”Biochem. Biophys. Res. Comm.46(2):1493-1498.
Fricker et al. (1995) “Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates”The Journal of Pharmacology and Experimental Therapeutics274:826-832.
Fuessl et al. (1987) “Oral Absroption of the Somatostain Analogue SMS 201-995: Theoretical and Practial Implications”Clinical Science72:255-257.
Garber et al. (1992) “Turnove of synthetic class A amphipatich peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties.”Arteriosclerosis and Thrombosis, 12(8):886-894.
Garber et al. (1997)Circulation96-I-490.
Gaber et al. (1999) “Protection against Atherosclerosis in Mice by a Synthetic Class A Amphipatic Peptide Analog of Apolipoprotein A-I.”Circulation100: 2838.
Garber et al. (2001) “A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis.”Journal of Lipid Research42: 545-552.
Glomset (1968) “The Plasma lecithin: cholesterol acytransferase reaction.”J. Lipid Res.9:155-167.
Gong et al. (1994) “Structural and functional properties of human and mouse apolipoprotein A-I,”Biochim. Biophys. Acta1213:335-342.
Gurfinkel et al. (2002) “Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions, The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study” Circulation 105:2143-2147.
Hamase et al. (2001) “Determination of Free D-Proline and

Affiliated with

Also associated with

Rating

Orally administered peptides to ameliorate atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Orally administered peptides to ameliorate atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally administered peptides to ameliorate atherosclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3668851